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Abstract 
Pompe disease (PD) is an autosomal recessive disease caused by partial or complete 
deficiency of the lysosomal hydrolase acid alpha-glucosidase, resulting in 
accumulation of glycogen in various tissues. It affects primarily the skeletal, smooth 
muscle and cardiac system. Pompe disease clinically presents as a continuum in its 
age of onset and multisystem involvement and is often fatal. Diagnosis can be 
difficult due to nonspecific phenotype of the disease. Enzyme replacement therapy 
(ERT) is the standard treatment for the disease since 2006. Although of considerable 
clinical benefit to some patients, there are significant limitations to ERT. Studies in 
novel therapeutic approaches show positive outcomes. In the context of therapeutic 
options, the earliest diagnosis and initiation of treatment can make a difference. Early 
identification through newborn screening and more effective therapies will hopefully 
lead to improved outcomes for patients with Pompe Disease. 
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Abbreviations:  
 
CRIM: cross-reactive immunological material  
 
CN: CRIM negative 
 
CP: CRIM positive 
 
DBS: dried blood spot 
  
PD: Pompe Disease 
 
ERT: Enzyme Replacement Therapy  
 
FVC: Forced Vital Capacity 
 
GAA: acid α-glucosidase 
 
HSAT: high sustained antibody titer 
 
HTCP: high-titer CRIM positive 
 
IOPD: infantile-onset Pompe Disease 
 
ITI: Immune Tolerance Induction 
 
LOPD: late-onset Pompe Disease 
 
NBS: Newborn Screening 
 
rh-GAA: recombinant human acid a-glucosidase 
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Introduction 
Pompe disease (PD) (OMIM:232300), 
also termed glycogen storage disease 
type II or acid maltase deficiency, is a 
rare genetic deficiency of lysosomal 
acid α-glucosidase (GAA). PD is an 
autosomal recessive disease and 
hundreds of mutations have been 
identified in the GAA gene. Certain 
mutations correlate with different 
phenotypes of PD (Nascimbeni et al., 
2008) and are potentially specific to 
families, geographic regions or 
ethnicities (Hirschhorn and Reuser, 
2001; Leslie and Bailey, 2007). PD has 
an estimated frequency of 
approximately 1/40.000. The incidence 
of Pompe disease may vary, depending 
on geographic region, ranging from 
1:14.000 in African Americans to 
1:100.000 in individuals of European 
descent (Leslie and Bailey, 2007).  
The growing literature on PD reveals 
significant clinical variability 
regarding age of onset, organ 
involvement, degree of myopathy and 
rate of progression (Dasouki et al., 
2014). The two broad subtypes 
encountered in clinical experience are 
based on the age and the primary 
symptoms: the infantile-onset and the 
late-onset Pompe disease. The 
infantile-onset form of PD (IOPD) 
usually appears by age 1. In IOPD, the 
most common symptoms are 
hypotonia, generalized muscle 
weakness, developmental delay, 
cardiac defects and respiratory 
insufficiency (Chan et al., 2017). IOPD 
associated with cardiomyopathy is 
referred to as classic Pompe disease 
and in the absence of cardiomyopathy 
as non-classic Pompe disease. Classic 
IOPD is rapidly progressive and has a 
fatal outcome within the first two years 
of life if left untreated. The late-onset 
type of PD (LOPD) begins in 
childhood, adolescence, or adulthood. 
The most prominent manifestations in 
LOPD are progressive muscle 
weakness, gait abnormalities, exercise 
intolerance, lower back pain, feeding 
problems, respiratory insufficiency, 
orthopnea, sleep apnea and 
hepatomegaly (Chan et al., 2017). 
LOPD is usually milder than the 
infantile-onset forms of the disease.  
Interest in Pompe disease has grown 
significantly since the approval of the 
first specific enzyme replacement 
therapy (ERT) for this deficiency with 
recombinant human acid α-glucosidase 
(alglucosidase alfa) in 2006. ERT 
dosage is being studied especially in 
patients that lack clinical improvement 
(van der Ploeg et al., 2010; van Gelder 
et al., 2016). Since the advent of ERT, 
early diagnosis is vital as disease’s 
natural course may be altered. The 
gold-standard test for diagnosis is DBS 
(Llerena Junior et al., 2015). Definitive 
diagnosis of Pompe disease is being 
based on the molecular analysis of the 
GAA gene for the presence of two 
pathogenic allelic mutations. Newborn 
screening studies raise interest in 
incorporating dried blot spot GAA 
testing into newborn screening 
protocols (Bodamer et al., 2017; Chien 
et al., 2008).  
ERT and, currently studied, gene 
therapy are two therapeutic strategies 
for Pompe disease, yet, immune 
responses against GAA are a 
substantial drawback. With the advent 
of immunomodulation therapies, 
identification of patients at risk for 
developing immune response should 
be considered before commencing 
ERT (Banugaria et al., 2011).  
Detection of CN (Cross-reactive 
immunologic material-negative) 
patients can be achieved through 
Western Blot analysis and genetic 
analysis (Burton et al., 2017). Some 
additional therapeutic approaches 
currently investigated are chemical 
chaperones, enzyme modification and 
substrate reduction therapy (Byrne et 
al., 2017; Han et al., 2016; Kishnani et 
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al., 2017; Smith et al., 2013). 
Nevertheless, treatment remains 
challenging, particularly in patients 
who have profound deficiency of GAA 
activity. 
 
Genetic Basis 
PD is caused by recessive mutations in 
the autosomal GAA gene. The α-
glucosidase gene (NM 000152) is 
located on the long arm of 
chromosome 17 (chr17q25.3). GAA 
gene consists of 20 (19 coding) exons 
which encode 952 amino acids. Acid 
α-glucosidase has 4 isoforms, 2 
catalytically active sites, 3 disulfide 
bonds and 7 N-linked glycosylation 
sites. Many normal allelic variants 
exist in GAA gene and are responsible 
for the three known alloenzymes. GAA 
is synthesized as a membrane bound, 
catalytically inactive precursor which 
is sequestered in the endoplasmic 
reticulum. It undergoes modification in 
the Golgi complex, followed by 
transport into the secretory pathway, or 
into lysosomes where it is trimmed in a 
process at both the amino- and 
carboxyl-termini. Phosphorylation of 
mannose residues ensures efficient 
transport of the enzyme to the 
lysosomes via the mannose 6-
phosphate receptor. GAA catalyzes the 
hydrolysis of α1→4 glucosidic 
linkages in glycogen at acid pH. 
Specificity for glycogen is gained 
during its maturation.  
More than 450 mutations in GAA gene 
have been identified, which are 
catalogued at the Pompe Center of the 
Erasmus University (Rotterdam). 
Nonsense mutations, large and small 
gene rearrangements, and splicing 
defects have been reported 
(http://www.pompecenter.nl/). GAA 
mutations result in mRNA instability 
and/or severely truncated protein or an 
enzyme with significantly decreased 
activity. Mutations that result in 
complete absence of GAA enzyme 
activity are commonly seen in 
individuals with infantile-onset 
disease, whereas combinations of 
mutations that allow partial enzyme 
activity usually have a later-onset 
presentation
 
(Nascimbeni et al., 2008). 
The most common mutation in adults 
with LOPD (50-85%) is the pathogenic 
variant c.336-13T>G typically in the 
compound heterozygous state. An 
estimated 50-60% of African 
Americans with IOPD have the 
pathogenic variant p.Arg854Ter 
(c.2560C>T). The p.Asp645Glu 
(c.1935C>A) variant is common in 
Chinese with IOPD (40-80%). In these 
populations targeted analysis for 
pathogenic variants can be useful
 
(Hirschhorn and Reuser, 2001; Leslie 
and Bailey, 2007). 
 
Diagnosis 
Diagnosis of Pompe disease can be 
made clinically based on a typical 
clinical presentation with limb 
weakness, difficulty walking or limb 
girdle dystrophy. Patients presenting 
with a limb-girdle syndrome or 
dyspnea secondary to diaphragm 
weakness should undergo further 
testing. Typically, IOPD patients 
present with hypotonia, upper and low 
limb weakness, macroglossia, 
hepatomegaly, progressive 
hypertrophic cardiomyopathy and 
cardio-respiratory insufficiency. LOPD 
patients usually present with slowly 
progressive limb girdle weakness, 
respiratory deterioration, rigid spine 
syndrome, scoliosis, low body mass, 
ptosis, bulbar palsy and urinary 
incontinence. The pathologic 
accumulation of glycogen in several 
tissues in PD show the following 
clinical correlations: diaphragm and 
intercostal muscles - respiratory 
failure, proximal skeletal muscle - 
progressive limb-girdle myopathy, 
genioglossus - tongue weakness, 
extraocular muscles - unilateral or 
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bilateral ptosis, smooth muscle – 
abdominal 
pain/nausea/vomiting/diarrhea/urinary 
incontinence, and cerebral vasculature 
- cerebral aneurysm (Dasouki et al., 
2014). The nonspecific phenotype of 
Pompe disease leads to consideration 
of different conditions (Table 1) (Chan 
et al., 2017; Llerena Junior et al., 
2015). Early involvement of 
respiratory muscles preceding muscle 
weakness may differentiate LOPD 
from other neuromuscular diseases, in 
which respiratory insufficiency occurs 
after loss of ambulation (Llerena 
Junior et al., 2015). 
Concurrently, diagnosis can be based 
on the following (Barba-Romero et al., 
2012; Bodamer et al., 2017; Burton et 
al., 2017; Chien et al., 2008; Llerena 
Junior et al., 2015): 
 Physical examination 
 Spirometry, FVC change 
 Blood biochemistry analysis (CK, 
ALT, AST, LDH), urine analysis 
(Glc4) 
 Dried blood spot testing (DBS) 
 Confirmation: GAA activity in 
lymphocytes, genetic testing 
Physical examination should focus on 
the muscular and respiratory systems. 
Clinical evaluation must include 
manual assessment –Medical Research 
Council (MRC) scale– or 
quantification of muscle strength 
combined with the performance of 
functional tests such as the Gowers 
maneuver and gait assessment (Barba-
Romero et al., 2012). Patients may 
demonstrate a positive Gower’s sign 
and waddling gait. A positive 
Trendelenburg’s sign and a positive 
Beevor’s sign may also be observed 
(Chan et al., 2017).  
Spirometry is very useful for detecting 
respiratory impairment that is common 
in LOPD and may even occur in the 
presymptomatic stage. It is very 
helpful to measure the change of 
forced vital capacity (FVC) in the 
upright and lying supine positions. A 
decrease by more than 10% in FVC 
from the upright to the supine position 
suggests weakness of the diaphragm 
(Chan et al., 2017).  
Elevations of creatine kinase (CK), 
aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), 
lactate dehydrogenase (LDH) and 
urinary glucose tetrasaccharide (Glc4) 
levels are sensitive but non-specific 
indicators for Pompe disease (Barba-
Romero et al., 2012). These enzyme 
biomarkers can be helpful when trying 
to establish a diagnosis in a patient 
with a positive NBS result for Pompe 
disease. Other useful tests would be: 
muscle biopsy, electromyogram, 
muscle imaging MRI, 
electrocardiogram, echocardiogram, 
chest X-ray, polysomnography and 
nocturnal oximetry.  
Measurement of GAA activity in dried 
blood spots (DBS) is the recommended 
method for screening patients with 
suspicion of PD. Factors that need to 
be considered when evaluating the 
results of GAA enzymatic activity 
testing include the presence of a 
pseudodeficiency allele that can alter 
the residual enzyme level in a screened 
infant and the possibility that the assay 
conditions and procedures may not be 
optimal, leading to false-positive 
results (Burton et al., 2017). If clinical 
suspicion of PD persists, the test 
should be repeated (Llerena Junior et 
al., 2015). The finding must be 
confirmed by a second enzyme assay 
in another tissue (lymphocytes, 
fibroblasts or muscle) or molecular 
analysis of the GAA gene (Barba-
Romero et al., 2012; Llerena Junior et 
al., 2015). 
 
Newborn Screening  
The potential benefit of ERT and need 
for early intervention in PD has led to 
considering dried blood spot GAA 
testing as the basis for newborn 
Aristotle Biomedical Journal, Vol 2, No 1 e-ISSN: 2653-9748 
 
43 
 
Table 1: Differential diagnosis of Pompe Disease 
Muscular dystrophies 
 
Duchenne, Becker, limb-girdle types of muscular 
dystrophies 
Myotonic Dystrophy type 2 
Inflammatory myopathies Polymyositis 
Congenital myopathies Danon disease 
Metabolic myopathies 
Glycogen Storage disease types IIIa, IV, V and VII 
Mitochondrial myopathies 
Motor neuron disease Spinal muscular atrophy 
Neuromuscular junction 
disease Myasthenia gravis 
 
screening (NBS). Methods for NBS for 
PD are assays based on the analysis of 
enzyme activities by using artificial 
substrates in DBS, either by 
fluorometry, tandem mass 
spectrometry (MS/MS), or 
microfluidics combined with 
fluorometry
 
(Bodamer et al., 2017). 
Other methods are based on analysis of 
accumulating substrate, immune 
quantification, and/or immune capture 
activity of the enzyme of interest. 
Molecular sequencing of the GAA 
gene is important for confirmatory 
(second tier) testing after a positive 
newborn screen for Pompe disease
 
(Bodamer et al., 2017). Patients with 
classic IOPD identified through NBS 
and, therefore, commenced early on 
ERT presented better outcomes as 
demonstrated by the Taiwan NBS 
program
 
(Chien et al., 2015). This 
supports the need for the earliest 
possible identification of patients with 
classic IOPD.  
Early treatment often prevents 
morbidity and mortality. Thus, the 
diagnosis of classic IOPD cannot be 
delayed by waiting for the sequencing 
result. Patients with low enzyme 
activity should undergo cardiac 
evaluation, ideally by chest radiograph, 
ECG, and ECHO to detect classic 
IOPD immediately
 
(Burton et al., 
2017). The diagnosis of IOPD can be 
established after a positive NBS result 
when physical examination, 
echocardiography and elevated CPK  
 
support the diagnosis. The 
management of LOPD based on 
enzymatic and molecular analysis 
remains a clinical challenge, because 
these patients will be normal at the 
time of diagnosis. Patients will need to 
be followed closely in order that they 
begin ERT as soon as they present 
clinical pathology
 
(Kronn et al., 2017). 
Analysis of GAA enzyme activity in 
cultured skin fibroblasts may be 
helpful when LOPD is suspected or 
when asymptomatic individuals are 
ascertained through screening tests. 
 
Cross Reactive Immunological 
Material (CRIM) 
The combination of two deleterious 
mutations leads to a complete lack of 
GAA protein and an extremely low 
residual GAA activity (< 1%)
 
(Chan et 
al., 2017; Llerena Junior et al., 2015), 
such genotype is associated with the 
classic IOPD, which presents a clinical 
phenotype with a rapid progression. 
From an immunological standpoint, 
these individuals have no cross-
reactive material and are classified as 
Cross-Reactive Immunological 
Material (CRIM) negative patients. 
Patients with at least one mild 
mutation, that allows partial enzyme 
activity present a clinical phenotype 
with a slower progression. From an 
immunological point of view, these 
patients are classified as CRIM 
positive (Leslie and Bailey, 2007; 
Llerena Junior et al., 2015).
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The CRIM status can be predicted by 
Western blot analysis of cultured skin 
fibroblasts, a process that can take a 
few weeks, and by molecular genetic 
testing if the patient’s genotype has 
previously been associated with CRIM 
status
 
(Bali et al., 2012). A method for 
determining CRIM status using 
peripheral blood mononuclear cells has 
been reported
 
(Wang et al., 2014). This 
method can yield results within 48 to 
72 hours but there is still no clear 
conclusion about its validity
 
(Bali et 
al., 2015).
 
 
Enzyme Replacement Therapy 
Enzyme replacement therapy (ERT) is 
currently the standard-of-care 
treatment of Pompe disease. ERT is 
based on the intravenous 
administration of recombinant human 
GAA (rhGAA). Symptomatic patients 
should start the treatment when the 
diagnosis is established, whereas 
asymptomatic patients should start the 
ERT when the firsts symptoms appear 
or when functional tests show a decline
 
(Barba-Romero et al., 2012). Before 
beginning ERT it is necessary to 
perform a complete clinical and 
laboratory evaluation. During follow-
up it is important to monitor the 
efficacy of the ERT through manual 
assessment of muscle strength (MRC 
scale), spirometry, timed functional 
test and mobility scales (6-minute walk 
test) (Barba-Romero et al., 2012). The 
recommended dosage regimen of 
alglucosidase α is 20 mg/kg of body 
weight administered once every 2 
weeks. In some cases, 40 mg/kg doses 
have been given but there is no 
certitude about the clinical 
benefit(Broomfield et al., 2015). 
Treatment significantly improves 
motor, respiratory and cardiac 
function. However, residual disease 
persists, indicating that ERT is not 
completely effective in clearing 
glycogen and correcting all the 
associated underlying pathologies in 
the different systems(Chien et al., 
2015; Prater et al., 2012). Patients still 
present risks of arrhythmia (Kronn et 
al., 2017), while progressive 
respiratory weakness and pulmonary 
decline persist
 
(Regnery et al., 2012). 
The addition of recombinant enzyme 
into the systemic circulation cannot 
reverse GAA deficiency in the CNS 
because does not effectively cross the 
blood-brain barrier. Neurological 
problems in PD include hearing loss 
due to a problem in the cochlea or 
middle ear, hypernasal speech with a 
flaccid dysarthria and aspiration risk 
and delays or deficiencies in brain 
myelination (Chan et al., 2017; 
Mcintosh et al., 2018). Muscle 
weakness, including generalized 
weakness, decreased endurance, and 
persistent fatigue (Chien et al., 2013) is 
possibly attributed to autophagy 
buildup, poor accessibility of the 
skeletal muscle fibers to systemically 
delivered enzyme, low expression of 
mannose-6-phosphate receptors 
(M6PR), or epigenetic and 
environmental factors (Regnery et al., 
2012). Also, immunological responses 
to therapeutic enzyme often attenuate 
treatment efficacy (Doerfler et al., 
2016).
 
Studies showed that early diagnosis 
and timely treatment allow a better 
motor development and may lead to 
better long-term outcomes (Chien et 
al., 2013). Age at onset of treatment, 
the initial health status and condition 
of the patients at diagnosis are 
significant determinants of clinical 
response. The best response is seen in 
patients who have less muscle 
pathology (Thurberg et al., 2006). In 
patients with less-advanced disease, 
early initiation of ERT improves 
outcomes (van der Ploeg et al., 2010). 
In IOPD it is vital to commence ERT 
at the earliest time point possible due 
to the attendant risks associated with 
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the development of IOPD-relevant 
complications, especially 
cardiorespiratory failure followed by 
death (van Gelder et al., 2016).  
In a clinical study including IOPD 
patients, elevation of biomarkers and 
impairment of motor function was 
noticed over time on ERT. Increase in 
dosage or frequency to 20mg/kg/week 
or 40mg/kg/2weeks when clinical 
decline was noticed possibly lead to 
better outcomes, suggesting a 
dosage/frequency escalation over time 
on treatment (Chien et al., 2015). 
Another study including CRIM-
positive patients with classic IOPD, 
demonstrated that patients on ERT 
receiving increased doses (40 
mg/kg/week) performed better than 
those receiving 20 mg/kg/2weeks 
regarding motor function and 
respiratory involvement (Broomfield et 
al., 2015). Overall, patients who 
experience plateau or decline in motor 
function over time on therapy, seem to 
present some clinical benefit when 
treated with 40 mg/kg doses (Case et 
al., 2015; van der Ploeg et al., 2010). 
Physical therapy, such as gentle 
facilitation of movement with active, 
graded assistance in infants, and 
aerobic functional exercise with active 
assistance in adults might preserve 
motor and physiologic function in 
patients and maximize the benefits of 
ERT (Mellies and Lofaso, 2009). 
 
Immune Responses 
Antibody responses to the therapeutic 
enzyme may be without overt clinical 
significance or may lead to 
hypersensitivity reactions, decreased 
bioavailability, or decreased efficacy. 
A patient developed nephrotic 
syndrome from immune complex-
mediated nephritis when escalating 
doses of rhGAA were administered as 
part of an experimental immune 
tolerance regimen (Hunley et al., 
2004).  
CRIM status is an important predictor 
of response to ERT. CRIM-negative 
(CN) status has been associated with a 
poor prognosis, attenuated response to 
ERT and tendency to develop high 
antibody titers (Banugaria et al., 2011; 
Kishnani et al., 2010). Patients who are 
identified as having CN status, have a 
complete deficiency of endogenous 
GAA. Thus, rhGAA is perceived as a 
foreign protein by the immune system 
in these patients, resulting in the 
development of anti-GAA B- and T-
cells that render ERT ineffective 
(Banugaria et al., 2011). CN patients 
tend to do poorly on ERT with death or 
need for invasive ventilation (Mellies 
and Lofaso, 2009). It is recommended 
to determine the CRIM status of each 
patient using GAA mutation analysis 
and Western-blot analysis on skin 
fibroblast cell extracts (Burton et al., 
2017). This step should be done before 
the first infusion of recombinant 
enzyme as it is essential to optimize 
the treatment by increasing doses 
and/or combining ERT with induction 
of immune tolerance in patients CN or 
having a poor response (Burton et al., 
2017; Kishnani et al., 2010). 
CN patients and some CRIM-positive 
(CP) patients develop high sustained 
antibody titer (HSAT) after exposure 
to ERT, which is considered to be a 
key factor in the poor response to ERT. 
Patients with HSAT have an attenuated 
therapeutic response to enzyme 
replacement therapy (Berrier et al., 
2015). In a retrospective study, it was 
found that high-titer CP (HTCP) 
patients showed a period of 
improvement in the first 6 months of 
enzyme replacement, after which they 
declined across all outcome measures, 
similar to CN patients (Banugaria et 
al., 2011). The CN and HTCP groups 
presented no statistically significant 
differences for any outcome measures 
and both patient groups responded 
poorly. The persistence of high titer 
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Table 2: Clinical trials on therapeutic approaches for Pompe Disease 
INTERVENTION/ TREATMENT PHASE ClinicalTrials.gov 
Identifier 
Drug: GZ402666 
Drug: alglucosidase alfa (GZ419829) 
Phase 3 NCT02782741 
Drug: ATB200 
Drug: AT2221  
Phase 
1/2 
NCT02675465 
Drug: Duvoglustat  Phase 2 NCT00688597 
Drug: rAAV1-CMV-GAA (study agent) 
Administration 
Other: RMST  
Phase 
1/2 
NCT00976352 
BMN 701 Phase 3 NCT01924845 
Drug: Clenbuterol 
Drug: Placebo 
Phase 
1/2 
NCT01942590 
Drug: Albuterol 
Drug: Placebo 
Phase 
1/2 
NCT01885936 
Drug: Salbutamol Phase 4 NCT02405598 
GZ402666: rhGAA conjugated to a synthetic branched hexasaccharide containing two 
terminal mannose-6-phosphate (M6P) residues, ATB200: rhGAA with an optimized 
carbohydrate structure, AT2221 (Miglustat): pharmacological chaperone, Duvoglustat 
(AT2220): pharmacological chaperone, RMST: Respiratory Muscle Strength Training 
BMN 701: fusion protein between GAA and insulin-like growth factor 2 (IGF2-GAA) 
Clenbuterol, Albuterol, Salbutamol: b2-agonists 
 
antibody correlated with the observed 
clinical decline in HTCP patients. 
Low-titer CP patients, in whom 
antibody titer was either persistently 
low or declining by 26 weeks, had a 
more favorable clinical outcome. The 
antibody response observed in CN and 
HTCP patients and the favorable 
outcome in low-titer CP patients 
further supports the correlation of poor 
clinical response to ERT with the 
increased and persistent antibody 
response.  
 
Immune Tolerance Induction 
While early diagnosis and treatment is 
significant in improving overall 
clinical outcomes in IPD, early 
diagnosis and initiation of treatment by 
itself does not prevent the development 
of antibodies against rhGAA. Immune 
tolerance induction (ITI) in the naïve 
setting has proven to be successful in 
preventing the development of 
antibody titers, which substantiates the 
use of ITI therapies in the ERT-naïve 
setting. Patients who present high-titer 
antibody response to ERT tend to 
respond more poorly and ultimately 
require invasive ventilation or die 
prematurely if not treated with ITI 
(Banugaria et al., 2011; Berrier et al., 
2015). Therefore, implementation of 
ITI in the naïve setting is of vital 
importance for CN patients with 
antibodies to rhGAA and CP patients 
at risk for a high-titer sustained 
immune response (Banugaria et al., 
2013; Berrier et al., 2015; Doerfler et 
al., 2016; Messinger et al., 2012). 
Successful ITI has been achieved, and 
results are encouraging with regimens 
of rituximab, methotrexate, and/ or 
immunoglobulin (intravenous 
immunoglobulin [IVIG]), which may 
prevent the deleterious immune 
response against alglucosidase alfa 
(Banugaria et al., 2013; Messinger et 
al., 2012). Studies using this ITI 
regimen concurrent with ERT support 
it is safely tolerated (Case et al., 2015; 
van Gelder et al., 2016). It seems to 
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improve clinical response and decrease 
antibody titers. Other ITI regimens, 
including inhibition of B cell activating 
factor using anti-BAFF monoclonal 
antibody and an inhibitor of the 
mammalian target of the rapamycin 
(mTOR) pathway (sirolimus), are 
being investigated (Doerfler et al., 
2016; Elder et al., 2013). 
 
Studies on Therapeutic Options 
Further modifications of the treatment 
that can address the limitations of 
ERT, such as a better uptake 
formulation and gene therapy are being 
explored (Table 2) (Byrne et al., 2017; 
Han et al., 2016; Kishnani et al., 2017; 
Smith et al., 2013).  
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